A RANDOMIZED, MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND

$105,700M01FY2009RRNIH

University Of New Mexico, Albuquerque NM

Investigators

Linked publications & trials

Paper 34166655 Paper 33478957 Paper 32446491 Paper 32111975 Paper 31691959 Paper 31427096 Paper 30737489 Paper 30631138 Paper 30487263 Paper 29872859 Paper 29256014 Paper 28526635 Paper 28283553 Paper 28279433 Paper 28199816 Paper 28120833 Paper 27766453 Paper 27455401 Paper 27423510 Paper 27321735 Paper 27142425 Paper 27074126 Paper 26938991 Paper 26865065 Paper 26305897 Paper 26080344 Paper 25145603 Paper 25117418 Paper 25102180 Paper 25018787 Paper 24973415 Paper 24931849 Paper 24931401 Paper 24698320 Paper 24627273 Paper 24531051 Paper 24529412 Paper 24447284 Paper 24378638 Paper 24370654 Paper 24139497 Paper 24135709 Paper 24083102 Paper 24067395 Paper 24060318 Paper 24029427 Paper 23905525 Paper 23867958 Paper 23802814 Paper 23797178 Paper 23770473 Paper 23576689 Paper 23567488 Paper 23498594 Paper 23441775 Paper 23437687 Paper 23389640 Paper 23361338 Paper 23054848 Paper 23015512 Paper 22994713 Paper 22982287 Paper 22926660 Paper 22873489 Paper 22847383 Paper 22814942 Paper 22773292 Paper 22748517 Paper 22744621 Paper 22720802 Paper 22644414 Paper 22562288 Paper 22551995 Paper 22492987 Paper 22453668 Paper 22421261 Paper 22412148 Paper 22211853 Paper 22186255 Paper 22131543 Paper 22119407 Paper 22111718 Paper 22007173 Paper 21946350 Paper 21930284 Paper 21727276 Paper 21719768 Paper 21713653 Paper 21631316 Paper 21613575 Paper 21596757 Paper 21515123 Paper 21455669 Paper 21454968 Paper 21399722 Paper 21359159 Paper 21311498 Paper 21285034 Paper 21229380 Paper 21193227

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is: 1. To evaluate the effect of darbepoetin on reticulocyte count, hematocrits, erythropoietin concentrations, and transfusion requirements in premature infants, compared to standard rHuEpo dosing and compared to placebo/sham dosing. 2. To evaluate the neurodevelopmental outcome of infants at age 18 to 22 months receiving darbepoetin compared to standard rHuEpo dosing and compared to placebo/sham dosing, and correlate neurodevelopmental outcomes with erythropoietin concentrations.

View original record on NIH RePORTER →